311P Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand

Abstract

Alectinib demonstrated significantly improved clinical outcomes in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in a randomized Phase III trial (ALEX). There is no study examining long-term health and economic outcomes of this first-line treatment of ALK+ advanced NSCLC compared with chemotherapy that has been a standard of care in Thailand.